Linagliptina Generis Phar

Linagliptin, the active ingredient in Linagliptina Generis Phar, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral dosage form for oral use. It is indicated for the treatment of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when diet, exercise, or other therapies are insufficient.

GNH USA supplies Linagliptina Generis Phar as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides regulatory‑approved batches to meet the needs of diverse healthcare settings.

Linagliptin is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus (monotherapy): achieves improved glycaemic control when diet and exercise alone are insufficient. Combination with metformin: provides additional HbA1c reduction in patients inadequately controlled on metformin alone. Adjunct to other oral antidiabetics: enhances overall glucose lowering when added to sulfonylureas, thiazolidinediones or SGLT2 inhibitors.

Linagliptin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract inflammation. - Headache: transient mild to moderate pain. - Upper respiratory infection: symptoms of cough and congestion. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: significant increase in ALT/AST levels. - Angioedema: swelling of face, lips, or airway. - Bullous pemphigoid: rare autoimmune blistering skin disease. - Anaphylaxis: life‑threatening allergic response.

Before initiating linagliptin therapy, consider the following precautions.

Renal impairment: no dose adjustment is required, but monitor renal function regularly. Hepatic impairment: use with caution and assess liver enzymes periodically. History of pancreatitis: discontinue if signs of pancreatitis develop. Hypersensitivity reactions: stop the drug immediately if rash, angioedema or anaphylaxis occur. Pregnancy and lactation: use only if the potential benefit outweighs the potential risk to the fetus or infant. Store at room temperature: keep in the original container, protect from moisture and light.

Linagliptin can interact with other medicines; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Concomitant insulin: increased risk of hypoglycaemia. - Sulfonylureas: heightened hypoglycaemia potential. - Strong P-glycoprotein inhibitors: may raise plasma linagliptin levels.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for possible anticoagulant effect changes. - Diuretics: observe renal function and electrolytes regularly.